Trial reportBMC women's health2025
Bacterial Vaginosis [BV] knowledge, attitudes and behavioural changes after BV diagnosis among women enrolled in a clinical trial in Boston, USA and Vulindlela, South Africa: a qualitative study.
Trial report in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06135974 (Phase 1 Trial of Multi-strain Lactobacillus Crispatus Vaginal Live Biotherapeutic Product), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1 Trial of Multi-strain Lactobacillus Crispatus Vaginal Live Biotherapeutic Product
Who cites it
2 citing papers in PubMed.
- Distribution and antimicrobial susceptibility profiles of bacterial isolates from vaginal discharge specimens among hospitalized patients in a tertiary maternal and child healthcare hospital in Shenzhen, China.Frontiers in microbiology · 2026Article
- International journal of sexual health : official journal of the World Association for Sexual Health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBacterial vaginosis (BV), the most common cause of vaginitis among reproductive age women, has high recurrence even after treatment. In addition to the physical risks of BV (e.g. increased HIV risk and adverse pregnancy outcomes such as preterm birth), the symptoms (malodour, itchiness, vaginal discharge) can cause emotional impacts (e.g. shame, embarrassment, self-consciousness). BV knowledge, attitudes, behavioural change(s) after diagnosis and other previous vaginal health concerns were explored among participants in a clinical trial assessing the safety and biologic effects of a vaginal live biotherapeutic product.
methodsIn-depth interviews (IDIs) were conducted with 37 female participants in a clinical trial in Boston, USA (n = 14), and Vulindlela, South Africa (SA) (n = 23). Interviews were audio recorded, transcribed and translated. Transcripts were coded and thematically analysed using NVivo.
resultsIn this study, previous BV diagnosis was lower in SA than USA (2(9%) versus 12(86%)), with 7(19%) overall reporting a previous STI. There were five key themes: (1) Prior BV and other vaginal health experiences: Although BV was not frequently diagnosed in SA, participants reported experiencing symptoms (discharge, itchiness and malodour). Conversely, USA participants had experiences with previous BV diagnoses. (2) Previous vaginal health seeking behaviour and treatments: Almost all participants from both sites had sought treatment from healthcare professionals for vaginal health concerns, with a few from both sites having used self-care practices. (3) BV knowledge, attitudes and reactions to BV diagnosis: BV knowledge in SA was poor compared with the USA, but most participants were relieved to receive help. (4) Behavioural changes because of BV: Vaginal hygiene practices changed and participants washed more frequently/used products to address malodour. Further, BV symptoms resulted in changes in sex acts and/or abstinence. (5) BV diagnosis disclosure patterns: Disclosure varied, with participants commonly disclosing to those who could provide them with support.
conclusionsBV knowledge, attitudes and experiences are related to previous diagnosis and treatment. Symptoms impact individuals' behaviours regardless of previous diagnosis, and can have psychosocial impacts which need to be addressed via appropriate counselling and treatment strategies. Ongoing research for effective BV prevention and treatment options that can be made available and accessible to women with BV globally is needed.
trial registrationSouth African National Clinical Trials Registry (SANCTR DOH-27-102023-8342; October 27, 2023) and ClinicalTrials.gov (NCT06135974; November 02, 2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.